A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

• Published in: Science translational medicine Vol. 9; no. 388
• Main Authors: Zhu, Qing, McLellan, Jason S, Kallewaard, Nicole L, Ulbrandt, Nancy D, Palaszynski, Susan, Zhang, Jing, Moldt, Brian, Khan, Anis, Svabek, Catherine, McAuliffe, Josephine M, Wrapp, Daniel, Patel, Nita K, Cook, Kimberly E, Richter, Bettina W M, Ryan, Patricia C, Yuan, Andy Q, Suzich, JoAnn A
• Format: Journal Article
• Language: English
• Published: United States 03.05.2017
• Subjects: Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antiviral Agents - pharmacokinetics; Antiviral Agents - therapeutic use; Female; Humans; Infant; Infant, Newborn; Male; Palivizumab - pharmacokinetics; Palivizumab - therapeutic use; Respiratory Syncytial Virus Infections - drug therapy; Respiratory Syncytial Virus Infections - prevention & control; Respiratory Syncytial Virus Vaccines - therapeutic use; Respiratory Syncytial Viruses - drug effects; Respiratory Syncytial Viruses - pathogenicity

Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associat...